Cargando…
Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604263/ https://www.ncbi.nlm.nih.gov/pubmed/33193448 http://dx.doi.org/10.3389/fimmu.2020.595289 |
| _version_ | 1783604107139874816 |
|---|---|
| author | De Souza, Andre Tavora, Fabio A. Mahalingam, Devalingam Munster, Pamela N. Safran, Howard P. El-Deiry, Wafik S. Carneiro, Benedito A. |
| author_facet | De Souza, Andre Tavora, Fabio A. Mahalingam, Devalingam Munster, Pamela N. Safran, Howard P. El-Deiry, Wafik S. Carneiro, Benedito A. |
| author_sort | De Souza, Andre |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7604263 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Frontiers Media S.A. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-76042632020-11-13 Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response De Souza, Andre Tavora, Fabio A. Mahalingam, Devalingam Munster, Pamela N. Safran, Howard P. El-Deiry, Wafik S. Carneiro, Benedito A. Front Immunol Immunology Frontiers Media S.A. 2020-10-19 /pmc/articles/PMC7604263/ /pubmed/33193448 http://dx.doi.org/10.3389/fimmu.2020.595289 Text en Copyright © 2020 De Souza, Tavora, Mahalingam, Munster, Safran, El-Deiry and Carneiro. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| spellingShingle | Immunology De Souza, Andre Tavora, Fabio A. Mahalingam, Devalingam Munster, Pamela N. Safran, Howard P. El-Deiry, Wafik S. Carneiro, Benedito A. Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response |
| title | Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response |
| title_full | Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response |
| title_fullStr | Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response |
| title_full_unstemmed | Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response |
| title_short | Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response |
| title_sort | commentary: gsk-3 inhibition as a therapeutic approach against sars cov2: dual benefit of inhibiting viral replication while potentiating the immune response |
| topic | Immunology |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604263/ https://www.ncbi.nlm.nih.gov/pubmed/33193448 http://dx.doi.org/10.3389/fimmu.2020.595289 |
| work_keys_str_mv | AT desouzaandre commentarygsk3inhibitionasatherapeuticapproachagainstsarscov2dualbenefitofinhibitingviralreplicationwhilepotentiatingtheimmuneresponse AT tavorafabioa commentarygsk3inhibitionasatherapeuticapproachagainstsarscov2dualbenefitofinhibitingviralreplicationwhilepotentiatingtheimmuneresponse AT mahalingamdevalingam commentarygsk3inhibitionasatherapeuticapproachagainstsarscov2dualbenefitofinhibitingviralreplicationwhilepotentiatingtheimmuneresponse AT munsterpamelan commentarygsk3inhibitionasatherapeuticapproachagainstsarscov2dualbenefitofinhibitingviralreplicationwhilepotentiatingtheimmuneresponse AT safranhowardp commentarygsk3inhibitionasatherapeuticapproachagainstsarscov2dualbenefitofinhibitingviralreplicationwhilepotentiatingtheimmuneresponse AT eldeirywafiks commentarygsk3inhibitionasatherapeuticapproachagainstsarscov2dualbenefitofinhibitingviralreplicationwhilepotentiatingtheimmuneresponse AT carneirobeneditoa commentarygsk3inhibitionasatherapeuticapproachagainstsarscov2dualbenefitofinhibitingviralreplicationwhilepotentiatingtheimmuneresponse |